GSK's stock has been a poor performer for years. But recently, the pharma stock keeps setting new 52-week highs, thanks to its blockbuster vaccines.
Unlike many of its peers, GSK just reported a big year-over-year jump in vaccine sales - and there's more growth to come, as the pharmaceutical company expands both its pipeline and the geographical reach...
The era of the giant pharmaceutical conglomerate is coming to a close, but consumer-focused Haleon stock looks set to deliver healthy returns through long-term economic cycles.
GSK stock could be a bargain.
/PRNewswire/ -- More than 53 million Americans provide care to family members or loved ones,1 but an overwhelming 4 out of 5 Americans say that pain has...
June S&P 500 futures (ESM23) are up +0.29%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.61% this morning after three major U.S. benchmark indices finished the regular session mixed as weaker-than-expected...
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment
Not for release, publication or distribution, directly or indirectly, in or into any jurisdiction into which such distribution would be unlawful. This notice...
Activist investor Dan Loeb has taken a nearly $1 stake in Colgate-Palmolive. He wants the company to unload its pet food business.Â